3 Popular Biotech Stocks to Buy on Sector Buzz

popular biotech stocks

Over the past years, the biotech sector has grown at a breakneck pace, so it’s only natural that biotech stocks have emerged as one of the more popular sectors among investors during this period. The coronavirus pandemic has sent the markets into a tailspin.

The weakness and volatility in the markets are real; however, there are certain stocks that could still help investors make money in these trying times. Biotech stocks could well prove to be the sector that investors need to look into. There are many biotech companies working in various fields that could be tracked. Here is a quick look at 3 popular biotech stocks that could be worth tracking right now:

Popular Biotech Stocks to Buy: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

popular biotech stocks

One of the more interesting biotech stocks in the market at this point is Vertex Pharmaceuticals. The company dominates the market for medicines meant for cystic fibrosis (CF) treatment.

Vertex is consistently profitable and has an enviable pipeline of products. The company has three medicines that have made it profitable and are approved to treat half of the CF patients in Australia, Europe, and North America. Those regions collectively have 75,000 CF patients. One of its products, Trikafta, was named by the pharmaceutical industry market research firm EvaluatePharma as the most valuable R & D program in the industry.

Vertex has delivered strong financial results in recent times, and in the full financial year 2019, the company recorded product revenue growth of $4.16 billion. That reflects a year-on-year rise of 37%. The earnings per share after adjustments hit $5.33, which reflects a handsome rise of 31%.

The company is building towards higher growth patiently and has emerged as one of the stocks to watch in the market. More importantly, Vertex has a cash pile of $3.8 billion, which will definitely help it to develop its business further in 2020.

Popular Biotech Stocks to Buy: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical has emerged as another promising biotech stock in recent times. The company is involved in developing treatments for rare genetic diseases in children and is on track to become profitable. In the financial year of 2019, BioMarin grew its revenues by 14% to hit $1.7 billion.

>> 3 Semiconductor Stocks All Set to Outperform This Quarter

More importantly, the company’s net losses dropped from $77.2 million in 2018 to $23.8 million in 2019. BioMarin expects to become profitable in 2019 and has projected that its revenues for the year should be between $1.95 billion and $2.05 billion. The projected earnings per share is $0.30, and in 2021, is expected to go up to $1.15.

Additionally, BioMarin also has two highly promising products in the pipeline, which will help the company’s long-term growth prospects. One of those products is valrox, which is meant to treat hemophilia A patients. The United States Food and Drug Administration has granted a priority review to valrox.

BioMarin’s share price has not moved much in recent times, but with profitability on the horizon and a price to sales ratio of 7.5, this could be a compelling stock to track.

Popular Biotech Stocks to Buy: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

popular biotech stocks

One biotech stock that has emerged as a promising proposition in recent times is Alexion Pharmaceuticals. The stock is trading at cheap valuations currently, and considering the fact that it develops medicines for rare diseases, it is worthwhile to have a closer look at it. The stock is currently trading at 7 times its future earnings per share and 10 times its 2020 cash flow.

The fact that Alexion works on medicines for very rare diseases keeps it immune from intense competition, something that could work in its favor. Its niche work allows Alexion to sell its treatments at a premium price. Alexion has replaced its wildly successful product Soliris with Ultomoris, which should see the company raking in revenue in the foreseeable future.

Featured image: Pixabay

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of Streetsignals.com or its officers. The author is wholly responsible for the validity of all statements. Streetsignals.com was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay Streetsignals.com to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetsignals.com's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. Streetsignals.com does not render general or specific investment advice. Any information on Streetsignals.com should not be considered a recommendation to buy or sell any security. Streetsignals.com does not endorse or recommend the business, products, services or securities of any company mentioned on Streetsignals.com.

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.